NASDAQ$PIII
P3 Health Partners Inc · Q2 2026 earnings
Q2 2026 earnings · · After market close · Investor relations
Briefing
P3 Health Partners Inc reported improved operating results for Q2 2026 driven by higher revenue and lower medical expenses.
P3 Health Partners Inc achieved total operating revenue of $386.4 million in Q2 2026, up 9% year-over-year, with operating income of $41.2 million compared to a loss in the prior year. Net income was $15.7 million, though net loss attributable to Class A common stockholders was $2.1 million after preferred dividends. Medical margin improved significantly to $97.8 million.
- Total operating revenue reached $386.4 million, including $366.4 million in capitated revenue.
- Operating income turned positive at $41.2 million versus a $34.1 million loss in Q2 2025.
- Medical margin increased to $97.8 million from $30.6 million year-over-year due to lower medical claims expense.
- Net income was $15.7 million, but preferred stock dividends resulted in a $2.1 million net loss for Class A common stockholders.
Headline financials
Revenue & EPS history
P3 Health · Revenue · Quarterly
$386M
Revenue by segment
P3 Health · $386M total across 2 segments · Q2 2026
- Capitated revenue$366M—94.8%
- Other revenue$20M—5.2%
Forward guidance
No explicit forward guidance was provided in the Q2 2026 10-Q filing.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
-3.8%
Avg return
Earnings day
+1.6%
Avg return
5 days after
-2.0%
Avg return
30 days after
37%
7 / 19 earnings
Positive
+11.2%
Q1 2026
Best reaction
-36.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q4 2026 | +0.7% | -9.7% | — | |
| Q1 2026 | +11.2% | +194.4% | +239.9% | |
| Q3 2025 | +0.4% | -12.6% | -25.9% | |
| Q2 2025 | -2.5% | +5.4% | +23.9% | |
| Q1 2025 | -0.6% | -5.9% | -19.5% | |
| Q4 2024 | -4.5% | +1.1% | -1.2% | |
| Q3 2024 | -36.8% | -42.2% | -46.0% | |
| Q2 2024 | -2.5% | -8.7% | -24.1% | |
| Q1 2024 | +2.6% | -11.8% | -21.6% | |
| Q4 2023 | -13.3% | -22.4% | -56.3% | |
| Q4 2021 | +3.1% | -7.6% | -12.2% | |
| Q3 2023 | -2.1% | -8.8% | -19.0% | |
| Q2 2023 | +0.9% | -10.8% | -5.0% | |
| Q4 2022 | -5.9% | -12.7% | +15.5% | |
| Q3 2022 | -11.8% | -19.7% | -33.5% | |
| Q1 2022 | -5.9% | +2.1% | -16.8% | |
| Q2 2022 | -4.1% | +0.6% | -14.0% | |
| Q3 2021 | +0.1% | +0.3% | -19.9% | |
| Q2 2021 | -0.7% | -0.2% | +0.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro